Hyperparathyroidism, Secondary

"Hyperparathyroidism, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.

Descriptor ID	D006962
MeSH Number(s)	C19.642.355.480
Concept/Terms	Hyperparathyroidism, Secondary Hyperparathyroidism, Secondary Secondary Hyperparathyroidism Hyperparathyroidisms, Secondary Secondary Hyperparathyroidisms

Below are MeSH descriptors whose meaning is more general than "Hyperparathyroidism, Secondary".

Diseases [C]
Endocrine System Diseases [C19]
Parathyroid Diseases [C19.642]
Hyperparathyroidism [C19.642.355]
Hyperparathyroidism, Secondary [C19.642.355.480]

Below are MeSH descriptors whose meaning is related to "Hyperparathyroidism, Secondary".

Below are MeSH descriptors whose meaning is more specific than "Hyperparathyroidism, Secondary".

Hyperparathyroidism, Secondary
Chronic Kidney Disease-Mineral and Bone Disorder

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hyperparathyroidism, Secondary" by people in this website by year, and whether "Hyperparathyroidism, Secondary" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2008 and 2025

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2001	1	0	1
2002	0	1	1
2006	1	0	1
2008	1	1	2
2016	0	1	1
2025	2	0	2

Below are the most recent publications written about "Hyperparathyroidism, Secondary" by people in Profiles.

Bishop CW, Ashfaq A, Choe J, Strugnell SA, Johnson LL, Norris KC, Sprague SM. Extended-Release Calcifediol Normalized 1,25-Dihydroxyvitamin D and Prevented Progression of Secondary Hyperparathyroidism in Hemodialysis Patients in a Pilot Randomized Clinical Trial. Am J Nephrol. 2026; 57(1):109-119.

View in: PubMed
Ashfaq A, Choe J, Strugnell SA, Patel N, Sprague SM, Norris KC, Lerma E, Petkovich PM, Bishop CW, Ashfaq A. Adjunctive Active Vitamin D Decreases Kidney Function during Treatment of Secondary Hyperparathyroidism with Extended-Release Calcifediol in Non-Dialysis Chronic Kidney Disease in a Randomized Trial. Am J Nephrol. 2025; 56(4):490-499.

View in: PubMed
Alsafran S, Sherman SK, Dahdaleh FS, Ruhle B, Mercier F, Kaplan EL, Angelos P, Grogan RH. Preoperative calcitriol reduces postoperative intravenous calcium requirements and length of stay in parathyroidectomy for renal-origin hyperparathyroidism. Surgery. 2019 01; 165(1):151-157.

View in: PubMed
Torres A, Torregrosa V, Marcen R, Campistol JM, Arias M, Hern?ndez D, Fern?ndez C, Esforzado N, Paschoalin R, P?rez N, Garc?a AI, Del Amo M, Pom?s J, Gonz?lez Rinne A, Marrero D, P?rez E, Henr?quez F, D?az JM, Silva I, L?pez V, Perello M, Ramos D, Beneyto I, Cruzado JM, Mart?nez Castelao A, Bravo J, Rodr?guez M, D?az C, Crespo J, Anaya F, Rodr?guez ML, Cubero JJ, Pascual P, Romero R, Andr?s Belmonte A, Checa MD, Jim?nez C, Escuin F, Crespo M, Mir M, G?mez G, Bayes B, Gonz?lez MJ, Guti?rrez A, Cuberes M, Rodr?guez Benoit A, Garc?a T, Llamas F, Ortega A, Conde JL, G?mez Alamillo C. Mineral metabolism disorders, vertebral fractures and aortic calcifications in stable kidney transplant recipients: The role of gender (EMITRAL study). Nefrologia. 2016 May-Jun; 36(3):255-67.

View in: PubMed
Omije D, Norris K, Wang J, Pan D, Kermah D, Gupta A. Race is a major determinant of secondary hyperparathyroidism in uremic patients: comparative study of Blacks and Hispanics. Clin Nephrol. 2008 Oct; 70(4):312-8.

View in: PubMed
Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, Gutierrez O, Camargo CA, Melamed M, Norris K, Stampfer MJ, Powe NR, Thadhani R. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol. 2008 Jul; 19(7):1379-88.

View in: PubMed
Norris KC. Oral paricalcitol : a viewpoint by keith C. Norris. Treat Endocrinol. 2006; 5(5):326-7.

View in: PubMed
Friedman TC, Norris KC. The role of vitamin D in mild to moderate chronic kidney disease. Trends Endocrinol Metab. 2002 Jul; 13(5):189-94.

View in: PubMed
Maung HM, Elangovan L, Fraz?o JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis. 2001 Mar; 37(3):532-43.

View in: PubMed
Fraz?o JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000 Sep; 36(3):550-61.

View in: PubMed

People

Explore

Similar Concepts

Top Journals